| Literature DB >> 33166402 |
Clementine Gamonet1, Maxime Desmarets1,2, Guillaume Mourey1,3, Sabeha Biichle1, Sophie Aupet1, Caroline Laheurte4, Anne François5, Eric Resch6, Frédéric Bigey7, Delphine Binda2, Laurent Bardiaux8, Christian Naegelen3, Nadine Marpaux3, Fanny Angelot Delettre3, Philippe Saas1, Pascal Morel3, Pierre Tiberghien1,3, Jacques Lacroix9, Gilles Capellier10, Chrystelle Vidal2, Francine Garnache-Ottou1,3.
Abstract
Extracellular vesicles (EVs) are active components of red blood cell (RBC) concentrates and may be associated with beneficial and adverse effects of transfusion. Elucidating controllable factors associated with EV release in RBC products is thus important to better manage the quality and properties of RBC units. Erythrocyte-derived EVs (EEVs) and platelet-derived EVs (PEVs) were counted in 1226 RBC units (administered to 280 patients) using a standardized cytometry-based method. EV size and CD47 and annexin V expression were also measured. The effects of donor characteristics, processing methods, and storage duration on EV counts were analyzed by using standard comparison tests, and analysis of covariance was used to determine factors independently associated with EV counts. PEV as well as EEV counts were higher in whole-blood-filtered RBC units compared with RBC-filtered units; PEV counts were associated with filter type (higher with filters associated with higher residual platelets), and CD47 expression was higher on EEVs in RBC units stored longer. Multivariate analysis showed that EEV counts were strongly associated with filter type (P < .0001), preparation, and storage time (+25.4 EEV/µL per day [P = .01] and +42.4 EEV/µL per day [P < .0001], respectively). The only independent factor associated with PEV counts was the residual platelet count in the unit (+67.1 PEV/µL; P < .0001). Overall, processing methods have an impact on EV counts and characteristics, leading to large variations in EV quantities transfused into patients. RBC unit processing methods might be standardized to control the EV content of RBC units if any impacts on patient outcomes can be confirmed. The IMIB (Impact of Microparticles in Blood) study is ancillary to the French ABLE (Age of Transfused Blood in Critically Ill Adults) trial (ISRCTN44878718).Entities:
Mesh:
Year: 2020 PMID: 33166402 PMCID: PMC7656935 DOI: 10.1182/bloodadvances.2020001658
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529